NO20041086L - Aminoindazolderivatrer aktive som kinaseinhibitorer, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som inneholder dem - Google Patents

Aminoindazolderivatrer aktive som kinaseinhibitorer, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som inneholder dem

Info

Publication number
NO20041086L
NO20041086L NO20041086A NO20041086A NO20041086L NO 20041086 L NO20041086 L NO 20041086L NO 20041086 A NO20041086 A NO 20041086A NO 20041086 A NO20041086 A NO 20041086A NO 20041086 L NO20041086 L NO 20041086L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
processes
preparation
compositions containing
kinase inhibitors
Prior art date
Application number
NO20041086A
Other languages
English (en)
Inventor
Anna Vulpetti
Rafaella Amici
Anello Matteo D
Katia Martina
Barbara Salom
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of NO20041086L publication Critical patent/NO20041086L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Tires In General (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Photolithography (AREA)
NO20041086A 2001-09-26 2004-03-15 Aminoindazolderivatrer aktive som kinaseinhibitorer, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som inneholder dem NO20041086L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96216201A 2001-09-26 2001-09-26
PCT/EP2002/010534 WO2003028720A1 (en) 2001-09-26 2002-09-19 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
NO20041086L true NO20041086L (no) 2004-03-15

Family

ID=25505498

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041086A NO20041086L (no) 2001-09-26 2004-03-15 Aminoindazolderivatrer aktive som kinaseinhibitorer, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som inneholder dem

Country Status (19)

Country Link
US (1) US7511136B2 (no)
EP (2) EP1432416B1 (no)
JP (1) JP4542338B2 (no)
KR (1) KR20040047869A (no)
CN (1) CN1556702A (no)
AT (1) ATE495741T1 (no)
BR (1) BR0212841A (no)
CA (1) CA2460145C (no)
CZ (1) CZ2004359A3 (no)
DE (1) DE60238999D1 (no)
EA (1) EA007430B1 (no)
ES (2) ES2357502T3 (no)
IL (1) IL160744A0 (no)
MX (1) MXPA04001114A (no)
NO (1) NO20041086L (no)
NZ (1) NZ531765A (no)
PL (1) PL368347A1 (no)
WO (1) WO2003028720A1 (no)
ZA (1) ZA200401848B (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2848554A1 (fr) * 2002-12-12 2004-06-18 Aventis Pharma Sa Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
RU2339624C2 (ru) 2002-12-12 2008-11-27 Авентис Фарма С.А. Производные аминоиндазолов и их применение в качестве ингибиторов киназ
UA81790C2 (uk) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
ES2436524T3 (es) 2003-05-22 2014-01-02 Nerviano Medical Sciences S.R.L. Derivados de pirazolo-quinazolina, procedimiento para su preparación y su uso como inhibidores de cinasas
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US20050107386A1 (en) * 2003-11-19 2005-05-19 Rama Krishna Narla Methods of treating diseases and disorders by targeting multiple kinases
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
TW200526204A (en) 2004-02-03 2005-08-16 Pharmacia Italia Spa 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
ES2564804T3 (es) 2004-02-12 2016-03-29 Mitsubishi Tanabe Pharma Corporation Compuesto de indazol y uso farmacéutico del mismo
KR20060114022A (ko) * 2004-02-27 2006-11-03 에프. 호프만-라 로슈 아게 인다졸 유도체 및 그들을 함유하는 약학 조성물
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
EP1647549A1 (en) 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP5303271B2 (ja) 2005-07-19 2013-10-02 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤として有用な1H−チエノ[2,3−c]ピラゾール化合物
EP1919913A2 (en) 2005-08-25 2008-05-14 F.Hoffmann-La Roche Ag P38 map kinase inhibitors and methods for using the same
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
WO2007089646A1 (en) 2006-01-31 2007-08-09 Array Biopharma Inc. Kinase inhibitors and methods of use thereof
EP1999131B1 (en) 2006-03-03 2013-10-23 Nerviano Medical Sciences S.r.l. Bicyclo-pyrazoles active as kinase inhibitors
JPWO2008001886A1 (ja) * 2006-06-30 2009-11-26 協和発酵キリン株式会社 オーロラ(Aurora)阻害剤
DE102006030479A1 (de) * 2006-07-01 2008-03-20 Merck Patent Gmbh Indazolderivate
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
US8450336B2 (en) 2006-12-14 2013-05-28 Nps Pharmaceuticals, Inc Use of D-serine derivatives for the treatment of anxiety disorders
WO2008076446A1 (en) * 2006-12-18 2008-06-26 Coleman Peter R Accelerated opiate dependence detoxification process
WO2008074676A1 (en) 2006-12-19 2008-06-26 F. Hoffmann-La Roche Ag Pyrazolo [3, 4 -d] pyrimidine p38 map kinase inhibitors
WO2008074749A1 (en) * 2006-12-20 2008-06-26 Nerviano Medical Sciences S.R.L. Indazole derivatives as kinase inhibitors for the treatment of cancer
EP2120933B1 (en) 2007-02-27 2015-07-08 Nerviano Medical Sciences S.r.l. Isoquinolinopyrrolopyridinones active as kinase inhibitors
EP2003129B1 (en) 2007-06-11 2017-08-09 Nerviano Medical Sciences S.r.l. 1H-Pyrido[3,4-B]indol-1-one and 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-one Derivatives
EP2157859A4 (en) * 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
EP2313097B1 (en) 2008-07-24 2013-03-27 Nerviano Medical Sciences S.r.l. Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
WO2010069966A1 (en) * 2008-12-18 2010-06-24 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
BR112013008527A2 (pt) 2010-12-17 2016-07-12 Nerviano Medical Sciences Srl derivados de pirazolo-quinazolina substituídos como inibidores de cinase
EA023579B1 (ru) 2011-05-12 2016-06-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные производные индазола, активные в качестве ингибиторов киназы
WO2015143652A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
CN107709314A (zh) 2015-06-11 2018-02-16 巴斯利尔药物国际股份公司 外排泵抑制剂及其治疗性用途
DE102015012050A1 (de) * 2015-09-15 2017-03-16 Merck Patent Gmbh Verbindungen als ASIC-Inhibitoren und deren Verwendungen
TWI873098B (zh) 2018-07-03 2025-02-21 瑞士商諾華製藥公司 用於治療與sting活性相關之病症的化合物及組合物
US12297184B2 (en) 2018-10-03 2025-05-13 Tesaro, Inc. Niraparib salts
WO2021067801A1 (en) * 2019-10-03 2021-04-08 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
PY2089159A (es) * 2019-12-31 2022-05-11 Ifm Due Inc Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
CR20220565A (es) 2020-05-06 2023-01-13 Merck Sharp & Dohme Llc Inhibidores de il4i1 y métodos de uso
CN113666911B (zh) * 2020-08-11 2025-08-26 河南迈英诺医药科技有限公司 Fgfr抑制剂化合物及其用途
US20230258652A1 (en) * 2020-08-12 2023-08-17 Dh Technologies Development Pte. Ltd. Phenacylbromide-Based Mass Tags For Carboxyl And Phenolic Functional Group Containing Analytes
JP2024502474A (ja) 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Sting活性に関連する状態を治療するための、尿素を有するヘテロ二環式化合物または類似体およびその組成物
AU2022326463A1 (en) * 2021-08-10 2024-02-22 Novartis Pharma Ag Compounds and compositions for treating conditions associated with sting activity
JP2025504415A (ja) * 2022-01-12 2025-02-12 アイエフエム デュー インコーポレイテッド Sting活性に関連する病態を治療するための化合物及び組成物
WO2023137034A1 (en) * 2022-01-12 2023-07-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
EP4499612A1 (en) 2022-03-30 2025-02-05 Nerviano Medical Sciences S.r.l. Substituted 3-amino indazole derivatives as kinase inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US474964A (en) * 1892-05-17 Electrically-heated matrix-press
US28939A (en) 1860-06-26 Improvement in stills
US2478048A (en) * 1943-01-23 1949-08-02 Winthrop Stearns Inc Sulfanilamidoindazoles and method of production
BE626284A (no) * 1962-04-28
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
DE2458965C3 (de) 1974-12-13 1979-10-11 Bayer Ag, 5090 Leverkusen 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel
JPS51143010A (en) * 1975-06-04 1976-12-09 Kao Corp Stable bleaching detergent composition
DE2653005A1 (de) * 1975-12-03 1977-06-08 Sandoz Ag Neue organische verbindungen, ihre verwendung und herstellung
JPS5754175A (ja) * 1980-09-19 1982-03-31 Asahi Chem Ind Co Ltd Shinkina33aminoindazoorujudotai
DE3166987D1 (en) * 1980-09-18 1984-12-06 Asahi Chemical Ind 3-aminoindazole derivatives and process for preparation thereof
EP0090972B1 (en) * 1982-03-17 1990-05-30 Asahi Kasei Kogyo Kabushiki Kaisha Indazole derivatives
JPS6061569A (ja) 1983-09-16 1985-04-09 Asahi Chem Ind Co Ltd 新規な3位置換アミン誘導体
JPS60172969A (ja) * 1984-02-16 1985-09-06 Asahi Chem Ind Co Ltd インダゾ−ル誘導体の製造法
JP2567621B2 (ja) 1986-08-22 1996-12-25 塩野義製薬株式会社 フエノ−ル類またはフエニルアミン類のオルトシアノ化法
US4864032A (en) * 1987-07-02 1989-09-05 Ortho Pharmaceutical Corporation Process for the preparation of indazoles
FR2661669B1 (fr) 1990-05-04 1992-08-14 Francais Ciments Adjuvant pour produits du beton.
JP3148960B2 (ja) * 1993-04-12 2001-03-26 コニカ株式会社 写真用シアンカプラー
JP3245765B2 (ja) * 1994-07-05 2002-01-15 コニカ株式会社 写真用シアンカプラー
KR100457502B1 (ko) * 1995-06-02 2005-09-05 사노피-신델라보 옥사졸리디논유도체,그것의제법및치료학적사용
DE19534649A1 (de) * 1995-09-19 1997-03-20 Hoechst Ag 2-Cyano-3-mercaptocrotonsäureamide
CA2315720A1 (en) 1997-12-22 1999-07-01 Bayer Corporation Inhibition of p38 kinase activity using substituted heterocyclic ureas
DE69918542T2 (de) * 1998-04-30 2005-08-18 Abbott Gmbh & Co. Kg Substituierte trizyklische pyrazolderivate mit protein kinase aktivität
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
AU2001290912A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
US7135288B2 (en) * 2002-09-27 2006-11-14 Ut-Battelle, Llc Combinatorial synthesis of ceramic materials

Also Published As

Publication number Publication date
EP1432416A1 (en) 2004-06-30
EA007430B1 (ru) 2006-10-27
PL368347A1 (en) 2005-03-21
KR20040047869A (ko) 2004-06-05
NZ531765A (en) 2006-02-24
ES2357502T3 (es) 2011-04-27
WO2003028720A1 (en) 2003-04-10
CA2460145A1 (en) 2003-04-10
JP4542338B2 (ja) 2010-09-15
ZA200401848B (en) 2005-03-07
ES2380054T3 (es) 2012-05-08
EP1820503A2 (en) 2007-08-22
MXPA04001114A (es) 2004-05-20
CZ2004359A3 (cs) 2004-09-15
BR0212841A (pt) 2004-08-03
ATE495741T1 (de) 2011-02-15
EP1432416B1 (en) 2011-01-19
EP1820503A3 (en) 2008-05-21
EA200400476A1 (ru) 2004-08-26
IL160744A0 (en) 2004-08-31
EP1820503B1 (en) 2012-02-22
JP2005512967A (ja) 2005-05-12
DE60238999D1 (de) 2011-03-03
US7511136B2 (en) 2009-03-31
US20040254177A1 (en) 2004-12-16
CN1556702A (zh) 2004-12-22
CA2460145C (en) 2011-04-26

Similar Documents

Publication Publication Date Title
ZA200401848B (en) Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them.
NO20040547L (no) Amino-ftalazinonderivater aktive som kinaseinhibitorer, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende disse.
MXPA04000920A (es) Derivados de aminoisoxazol activos como inhibidores de la cinasa.
MXPA02012164A (es) Derivados de tiofeno activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden.
CA2486101A1 (en) Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
GB0102687D0 (en) Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
MXPA05009719A (es) Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
WO2003070236A3 (en) Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
GB0330043D0 (en) Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330042D0 (en) Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
DE602004017194D1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
DK1636236T3 (da) Pyrazolo-quinazolin-derivater, en fremgangsmåde til fremstilling deraf, og deres anvendelse som kinase-inhibitorer
NO20030381L (no) Bicyklopyrazoler som er aktive som kinaseinhibitorer, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder slikeforbindelser
WO2005005414A3 (en) Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
DE602004014163D1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
DK1906916T3 (da) Oftalmisk suspension, der omfatter et oftalmisk lægemiddel, en poloxamin og et tonicitetsregulerende glycolbaseret middel, anvendelse af sammensætningen til fremstilling af et medikament til behandling af oftalmiske lidelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application